Johnson & Johnson expects $2.5 billion in global sales from Covid vaccine this year

In this article

In this photo illustration a Johnson & Johnson logo is seen in front of a medical syringe and a vial with coronavirus vaccine.
Pavlo Gonchar | SOPA Images | LightRocket | Getty Images

Johnson & Johnson said Wednesday it expects to sell $2.5 billion of its Covid-19 vaccine, even as concerns mount over the shot’s effectiveness against the delta variant.

In releasing its second-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.

Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted EPS: $2.48 per share vs $2.27 expected.
  • Revenue: $23.31 billion vs $22.21 billion expected.

The company’s share price was up nearly 1% in premarket trading following the report.

This is a developing story. Please check back for updates.

Earnings

Products You May Like

Articles You May Like

ECB set to tweak guidance to reflect its new 2% inflation target
Teenagers: Don’t Lose This Summer Job Advantage
UK college offers medical students $13,700 in cash to defer their degree
IRS estimates of unpaid taxes are ‘unfounded,’ says Rep. Kevin Brady
Fintech keeps minting billionaires as Robinhood co-founders prepare for massive IPO

Leave a Reply

Your email address will not be published. Required fields are marked *